Perspectives on Gene Patents

AUTM Annual Meeting March 1, 2008

Gene Patents: A Controversial Topic

- On the one hand, patenting and licensing can induce the investment necessary to bring a quality product to market
- On the other hand, critics argue that genetic patents have impacted medical care
- The public debate ranges from the sensible to the sensational

Even a NY Times Bestselling Novel

- "Next," by Michael Crichton (2006)
 - Thriller based on genetic engineering run amok
- In an Author's Note, Crichton makes five recommendations:
 - Stop patenting genes
 - Establish guidelines for use of human tissues
 - Ensure data about gene testing is public
 - Avoid bans on research
 - Rescind the Bayh-Dole Act

...and Subsequent Legislation

- H.R. 977, "Genomic Research and Accessibility Act"
- The gist is to add the following new section to 35 U.S.C.10:

"Sec. 106. Prohibition on patent of human genetic material

"Notwithstanding any other provision of law, no patent may be obtained for a nucleotide sequence, or its functions or correlations, or the naturally occurring products it specifies."

Tech Transfer Practitioners Need To...

- Understand the debate and the very real issues on both sides
- Work toward creative solutions that minimize negative impacts on patient care, while still providing sufficient incentives for companies to develop new, useful and high-quality products

Today's Agenda

- An empirical perspective
- A clinical perspective
- An industry perspective
- A technology transfer perspective
- Open discussion

Our Panelists

Wayne Grody

Director, Diagnostic Molecular Pathology Laboratory, UCLA Medical Center

Lori Pressman

Private Consultant

Mark Rohrbaugh

Director, Office of Technology Transfer, National Institutes of Health

James Weseman

Director of Intellectual Property InVivoScribe Technologies, LLC

Wendy Streitz (Moderator)

Director, Policy, Analysis & Campus Services, OTT, University of Calif.